Pall Will Seek To Aid FDA In U.S. Leukocyte Filtration Initiatives
This article was originally published in The Gray Sheet
Executive Summary
Pall Corporation will aid FDA through broad-scale programs in implementing routine leukocyte filtration of the U.S. blood supply, the company says.
You may also be interested in...
Universal Leukocyte Reduction To Double Annual Blood Filtration Market
Universal leukocyte reduction of all blood units used for transfusions in the U.S. would roughly double the market for the blood filters to about $420 mil., annually.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.